Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-Term Safety and Efficacy of Somatuline Autogel in the Treatment of Neuroendocrine Tumours When Administered by Patients or Their Partners ("Home Injection Group") or Administered by Healthcare Professionals

NCT00747786 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00747786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00747786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Multicentre, Open Label, Non Interventional Programme to Assess the Long-Term Safety and Efficacy of Somatuline Autogel in the Treatment of Neuroendocrine Tumours When Administered by Patients or Their Partners ("Home Injection Group") or Administered by Healthcare Professionals
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
December 31, 2008
Completion date
August 31, 2013
Enrollment
40 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumors